← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Scarab Genomics, Llc
Madison, WI
$25,796,199
Total funding
19
Grants
Funding over time
peak $2.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,796,199 · 19
By mechanism
R44$23,865,029 · 12
R43$1,931,170 · 7
Investigators at Scarab Genomics, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Characterization of a low mutation rate E. coli in extended fermentation$1,554,424
R44 · FY2016 · GM
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain$1,000,000
R44 · FY2020 · AI
Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture$1,000,000
R44 · FY2020 · AI
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain$1,000,000
R44 · FY2019 · AI
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain$1,000,000
R44 · FY2021 · AI
Innate Immune Protection by Clean Genome E. coli$995,989
R44 · FY2011 · AI
Improved bacterial strains for therapeutic DNA and protein production$989,190
R44 · FY2009 · GM
Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture$961,744
R44 · FY2022 · AI
Production of antibody therapeutic fragments by reduced genome E. coli in continuous culture$944,508
R44 · FY2021 · AI
Development of a continuous microbial fermentation system using reduced genome E. coli that undergo programmed autolysis and generate nuclease post-production for the manufacture of biopharmaceuticals$937,537
R44 · FY2025 · GM
Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli$911,189
R44 · FY2019 · AI
A protease-deficient, low mutation rate E. coli for biotherapeutics production$910,959
R44 · FY2013 · GM
Increasing available choices for conjugate vaccine technology by producing carrier proteins in Scarab Genomicsâ reduced genome E. coli strains$877,755
R44 · FY2017 · AI
Characterization of a low mutation rate E. coli in extended fermentation$864,106
R44 · FY2017 · GM
An improved low-endotoxin Clean Genome E. coli strain for production of biological products$842,151
R44 · FY2024 · GM
Improved bacterial strains for therapeutic DNA and protein production$836,793
R44 · FY2010 · GM
An improved low-endotoxin Clean Genome E. coli strain for production of biological products$806,101
R44 · FY2025 · GM
Lysis-free extraction of biopharmaceuticals from the periplasm of Clean Genome E. coli$737,950
R44 · FY2020 · AI
Innate Immune Protection by Clean Genome E. coli$737,476
R44 · FY2012 · AI
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain$732,955
R44 · FY2014 · AI